Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Mayo Clinic
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Travera Inc
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Turning Point Therapeutics, Inc.
NRG Oncology
NRG Oncology
NRG Oncology
Eastern Cooperative Oncology Group
Hoffmann-La Roche
Eastern Cooperative Oncology Group
Emory University
Boehringer Ingelheim
University of California, San Diego
Emory University
National Cancer Institute (NCI)
Boehringer Ingelheim
Rigshospitalet, Denmark
Inhibrx Biosciences, Inc
Tanabe Pharma America, Inc.
TScan Therapeutics, Inc.
Mayo Clinic
Mayo Clinic
Cedars-Sinai Medical Center
Massive Bio, Inc.
Emory University
University of Kentucky
Sichuan Baili Pharmaceutical Co., Ltd.
Hookipa Biotech GmbH
University of California, San Diego
Marengo Therapeutics, Inc.
Hoffmann-La Roche
Numab Therapeutics AG
Regeneron Pharmaceuticals
Emory University
Eurofarma Laboratorios S.A.
Intensity Therapeutics, Inc.
University of Utah
University of California, San Francisco
Vaccinex Inc.
National Cancer Institute (NCI)
Travera Inc